Minerva Neurosciences Inc
NASDAQ:NERV
Minerva Neurosciences Inc
Cash from Financing Activities
Minerva Neurosciences Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Minerva Neurosciences Inc
NASDAQ:NERV
|
Cash from Financing Activities
$19.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Minerva Neurosciences Inc's Cash from Financing Activities?
Cash from Financing Activities
19.6m
USD
Based on the financial report for Dec 31, 2023, Minerva Neurosciences Inc's Cash from Financing Activities amounts to 19.6m USD.
What is Minerva Neurosciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
18%
The average annual Cash from Financing Activities growth rates for Minerva Neurosciences Inc have been 14% over the past three years , and 18% over the past ten years .